Skip to content
NewsBlazeAU – Lifestyle
Author:
RENEXXION IRELAND
Renexxion Presents Gastroparesis Treatment Update at H.C. Wainwright Conference
September 8, 2026
Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis
June 1, 2026
Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
May 4, 2026
Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026
April 16, 2026